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 Heme is an important biological metallo-cofactor that also works as a signaling 
molecule in cells. Despite its importance, heme trafficking and mobilization in the cell 
are currently not well understood, in part due to the limited ability to visualize and 
quantify heme in vivo.  This inconvenience has recently been overcome by the 
development of genetically encoded heme sensors by the Reddi lab.  Using these sensors, 
the Reddi lab has identified new heme trafficking factors and probed the spatio-temporal 
dynamics of heme mobilization1.  While the heme sensors are powerful tools for imaging 
and quantifying heme, improvements could be implemented that would allow for greater 
utility than is currently available due to particular limitations in the prototype sensors.  A 
current limitation in heme sensing is that the heme dissociation constants of the prototype 
sensors span a limited range. The high affinity heme sensor, HS1 (Kd
II ~ 10 pM and Kd
III 
= 9 nM) is quantitatively saturated in all sub-cellular compartments, including the 
cytosol, nucleus, and mitochondria, making it unsuitable for heme monitoring. The low 
affinity sensor, HS1-M7A (Kd
II = 20 nM and Kd
III = 2 uM) is ~20-50% saturated with 
heme in the cytosol, but ~ 0 % saturated in the nucleus and mitochondria, making it 
unsuitable for heme monitoring in these compartments. In an effort to broaden the utility 
of the heme sensors, we report herein an expanded library of sensors engineered to span a 
wide-array of heme affinities. Heme binding residues were mutated to Ala, Cys, His, Lys, 
Met, Ser and Tyr to generate a panel of 47 new mutants which were found to be between 
0 and 100% saturated when expressed in the yeast cytosol. These new tools will enable 
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Heme (iron protoporphyrin IX) is an important metallo-cofactor of numerous 
proteins and consists of an iron center enclosed in an organic tetrapyrrole ring.  It is used 
in a wide range of proteins with varying functions including electron transfer,2 gas 
transport,3 and gas sensing.4  Heme, while being vital to life, is also toxic to cells because 
of its ability to produce reactive oxygen species (ROS) which cause lipid peroxidation.5  
This is not an issue when considering the largest heme pool, which is the exchange-inert 
heme that is bound to heme-proteins, because this heme is tightly bound and unavailable 
to produce oxygen radicals.  In recent years however it has been shown that a labile heme 
pool is present in the cell for signaling and other processes.6  This dichotomy of heme 
requires that it must be tightly regulated and buffered in the cell to prevent oxidative 
damage, while still being available for signaling and mobilization throughout the cell.  
These facts bring about a fundamental question: how is heme regulated in the cell?  This 
question quickly becomes complex due to many unanswered questions, such as, what is 
buffering heme and how much labile heme resides in different compartments of the cell, 
or what is transporting heme within the cell?  In an effort to help answer these questions 
the work described in this thesis builds upon a previously developed heme sensor to 





1.2 Regulation and Transport of Heme 
Heme is synthesized through the Shemin pathway, seen in Figure 1, starting in the 
mitochondrial matrix with the production of 5-aminolevulinate (ALA), through the 
condensation of glycine and succinyl-CoA.7  ALA is then transported outside the 
mitochondrial matrix where it goes through three condensation reactions to produce 
Uroporphyrinogen III.7  Uroporphyrinogen III is then partially decarboxylated to form 
Coproporphyrinogen III.7  Coproporphyrinogen III is then transported to the 
intermembrane space where it goes through an oxidative decarboxylation forming two 
vinyl groups on the molecule, and one further oxidation that yields protoporphyrin IX 
back inside the mitochondrial matrix.7  The final step is the insertion of Fe2+ into the 
protoporphyrin ring.7  At this point a fully developed heme molecule is available to be 
shuttled throughout the cell.  This is where the current understanding of heme dynamics 
comes into play. 
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Figure 1. A - Heme synthesis pathway beginning with 5-aminolevulinate.  B – Proposed 
machinery of heme synthesis with experimentally undefined components labeled with a 
“?”.  Reprinted (adapted) with permission from Hamza et al. Copyright Elsevier 2012.7 
 
 
It is currently known that heme is required in virtually every organelle in the cell; 
however, the process by which heme traverses the cell from the mitochondria to the 
organelles remains elusive.8  The toxic effects of heme requires it to be buffered in some 
way to prevent from oxidative damage and cell death that would incur while moving 
throughout the cell, which leads to the question of how is heme transported throughout 
the cell?  Currently there are two prevailing ideas when it comes to how heme moves 
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through the cell.  The first is that heme is transported in specialized vesicles around the 
cell creating a sub environment capable of limiting the oxidative stress of the heme.9  The 
second is that specialized proteins called heme chaperones are capable of buffering and 
carrying heme from place to place in the cell, while preventing heme’s production of 
ROS.7  It stands to reason that perhaps both of these mechanisms are in play to mitigate 
the possibility of oxidative stress.  The assumed pathway by which heme is shuttled 
throughout the cell can be seen in Figure 2, in which one will notice that most of the 
suspected transporters and chaperones of heme are currently unknown.  Development of 
heme sensors capable of being targeted to organelles and sensing changes in labile heme 
(LH) will be vital in further understanding of how heme is transported in the cell and 
uncovering the proteins involved in these processes.  This statement is bolstered by the 
fact that a possible heme buffering protein was discovered using the first generation heme 
sensor that is subject for further development in this thesis.  While the venture to uncover 
heme regulation and transportation is noble on its own, it is also important in 




Figure 2. Proposed model of heme transport in the cell.  Heme (Red Cross) is shown 
traversing the cell to arrive at the different organelles in which it is needed, while 
pathways taken to reach each organelle is depicted with an arrow.  Unknown pathways 
are indicated with a Black arrow and a “?” while known pathways are grey.  Reprinted 




1.3 Heme and Diseases 
Heme has been linked to many diseases, including neurodegenerative diseases,10 
colon cancer,11 and vascular diseases.12  The absolute role of heme in disease is still being 
investigated; however, its ability to produce ROS and integrate with cell membranes is at 
the core of what makes heme a suspect in many diseases.  This can be seen with the 
suspected role that heme plays in both Alzheimer’s disease as well as in colon cancer. 
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Alzheimer’s disease (AD) is the most common neurodegenerative disorder in the 
United States, affecting ~ 5 million people in 2013, and is the 5th leading cause of death 
in people over the age of 65.13  AD is distinguished by the buildup of senile plaque, 
which is composed of amyloid-β (Aβ) and Tau proteins, in the brain.14  Heme 
metabolism and regulation is altered in AD brains14 alongside proteins that interact with 
heme, such as heme oxygenase.15  Because of this, heme has been suspected to play 
several roles in the development of AD.  It has been shown that heme can interact with 
Aβ, alongside Cu, to produce a peroxidase complex capable of generating ROS that could 
lead to the oxidative stress and death of neuronal cells in AD.16  Heme has also been 
shown to prevent the aggregation of Aβ plaques, allowing for Aβ monomers to more 
easily traverse brain tissue.17  The effects of this are not well understood, but it could be 
that heme is compounding the problem of AD in the brain by allowing smaller Aβ 
monomers to spread through the brain better than the aggregates found in plaque, while 
also producing ROS that are causing cytotoxicity and cell death. 
Colon cancer is one of the leading causes of cancer in the United States, and other 
Western countries.18 While some genetic factors have been shown to be important in the 
development of colon cancer, it is clear that environmental factors are key to the 
development of the disease.18  Heme has long been suspected as a key contributor to the 
development of colon cancer. This is supported by numerous epidemiological studies, 
which underscored the high meat content in Western diets compared to the limited meat 
diets of Asian countries.  More recent rodent studies however have shown a more direct 
link to heme in the development of colon cancer.  The mechanism by which heme may 
induce colon cancer is still unclear; however, there are several ideas as to how it may be 
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occurring.  The first explanation for heme’s role in the progression of colon cancer is that 
heme increases the redox stress on the colon which in turn causes DNA damage and 
increased hyperproliferation.11  More recent studies are suggesting that this explanation 
may be somewhat too simplistic.  It has recently been suggested that heme is altering the 
microbiota of the gut that in turn is increasing progression of colon cancer.19  This result 
shows that heme may play a more metabolic role in the development of colon cancer 
while also providing the oxidative environment capable of causing the DNA damage that 
ultimately leads to colon cancer. 
In all of these cases, our understanding of how heme affects the progression of the 
disease is limited by the limited knowledge of heme regulation and the inability to 
visualize and quantify labile heme in live cells. 
 
1.4 Sensing Heme 
Sensors for the detection of metal ions in biology have flourished in recent years 
with dozens of sensors being developed for a wide range of metals.20  Development of 
both small molecule and genetically encoded protein-based sensors has allowed 
researchers to study transition metal ions, particularly zinc and copper, with high 
sensitivity and spatial resolution that were previously impossible at the single cell level.20 
Imaging and quantifying heme in cells using fluorescent sensors represents a 
challenging task.  Compared to fluorescent probes for transition metal ions, the creation 
of genetically encoded sensors, capable of high contrast imaging of heme in the cell, is 
particularly challenging. This is in part due to the ability of heme to act as a fluorescence 
quencher through Förster resonance energy transfer (FRET).  This significantly limits the 
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ability to create heme sensors using cyan fluorescent protein (CFP) and yellow 
fluorescent protein (YFP) FRET pair, which have been commonly employed for the 
design of genetically encoded metal ion sensors.20  This problem necessitates that any 
sensor used to detect heme by a FRET approach must use a fluorescent protein outside 
the range of heme absorbance and/or have heme binding occur significantly far from the 
fluorescent proteins to increase sensitivity of the sensor and intensity of the signal. In 
light of this, two separate sensors have been developed in an effort to create a cellular 
heme sensor. 
Song et al. developed a sensor that uses FRET between CFP and YFP to detect 
heme.21  These fluorescent proteins are linked with two heme transfer proteins between 
them, which allow for CFP and YFP to be brought together in the presence of heme and 
allow for FRET to occur.21  Because of its seemingly modular setup and ease of use in 
investigation, this technique has been previously used for the design of numerous metal 
ion sensors.20  Significant differences in LH levels were detected in a range of different 
mammalian cancer cell lines and in different compartments of the cell.21 
A somewhat different approach was taken by the Reddi lab at Georgia Tech, who 
developed a genetically encoded heme sensor that uses FRET between enhanced green 
fluorescent protein (EGFP) and heme as a signal for sensing LH in the cell.1  In doing this 
the sensor uses the ability of heme to quench fluorescence as part of its readout while 
providing a heme-independent readout with mKATE2 to provide a ratiometric sensor.1 
The basic framework of the sensor is an EGFP- cytochrome b562 (cyt b562) fusion 
protein developed by Arpino et al.22  This fusion protein was created using combinatorial 
mutagenesis which ultimately yielded CG6, a mutant EGFP with Cyt b562 inserted 
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between residue 39 and 40.22  This scaffold places the fluorophore of EGFP within ~ 17 
Å of heme which is enough to give ~100% energy transfer when heme is bound to Cyt 
b562.
22  This energy transfer gives an Off/On signal that indicates heme bound or 
unbound.  Purified CG6 can be used to study, for example, the in vitro heme transfer 
between proteins or to determine the binding affinity of heme-binding proteins based on 
competition titrations.  However, application of the probe for in vivo experiments is 
limited due to the intensity based readout obtained from this sensor rather than a 
ratiometric readout.  A ratiometric readout is preferred when experimenting in vivo 
because effects of sensor concentration, bleaching and several other factors can more 
easily be corrected. 
This leads to the next evolution of CG6, which is the addition of mKate2 to 
produce a ratiometric readout that can be used in the cell for quantifying buffered heme 
levels.  mKate2 is a red fluorescent protein that has an emission spectrum at 620 nm, just 
outside the range of heme absorbance.  This alongside the fact that the mKate2 Förster 
distance is approximately double that of eGFP’s suggests that mKate2 fluorescence is 
independent of heme.  This new sensor was given the name HS1 and was the first 
iteration of a genetically encoded ratiometric sensor for the detection of heme.  The 
structure of this sensor can be seen in Figure 3.  In order to obtain useful data one must 
take the ratio of eGFP fluorescence and dividing by the mKate2 fluorescence giving the 
eGFP/mKate2 ratio.  As heme binds to HS1 eGFP fluorescence decreases, lowering the 
overall eGFP/mKate2 ratio, therefore larger ratio values indicate low concentrations of 
heme while smaller ratio values indicate high heme concentrations.   
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It was determined, through titration and in situ studies of HS1, that HS1 was 
binding heme too tightly (Kd
II <1nM)1 to be useful in cellular studies and so a mutation 
was made in hopes of creating a sensor with a weaker binding affinity to heme.  This 
mutation was a HS1-M7A and was altered by replacing the Met7 axial binding ligand of 
Cyt b562 with an Ala.  The affinity of HS1-M7A (Kd
II ~25nM)1 appears to be in the range 
capable of detecting heme in the cytosol of yeast.  These sensors were validated with several 
in vitro tests that were completed to make sure that the sensors were only detecting 
changes in heme, that the sensors were not pH dependent, and that heme binding was 
reversible.1  Once the sensors were determined to be valid they were used to probe heme 




Figure 3. A – Ribbon structure of HS1 with each domain labeled.  The green box 
indicates the heme binding site of HS1.  B – Heme binding site of HS1 with heme and the 
two axial coordinating sites (His102 and Met7) indicated. Models are derived from the X-





Using these sensors, the cytosolic LH pool was determined to be ~20-40 nM in 
yeast1 which is in line with the previously proposed 10-100 nM range.24  From Figure 4, 
it can also be seen that the LH pool exists in three different states in the cytosol of yeast.1  
This was a novel observation suggesting that the LH pool may exist in a state of flux 
rather than remaining at a rather constant concentration, lending to the idea of heme 




Figure 4. Analysis of cytosolic heme using flow cytometry with HS1 and HS1-M7A. 
Green lines indicate saturated sensor. Red lines indicate normal yeast growth conditions. 
Blue lines indicate growth with succinylacetone (SA), which prevents heme production. 
Reprinted (adapted) with permission from Hanna et al. Copyright 2016 National 
Academy of Sciences.1 
 
 
As can be seen in Figure 5, nitric oxide (NO) was also shown to have a significant 
effect on cytosolic and nuclear heme pools, which is in line with previous studies.25  
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Glyceraldehyde phosphate dehydrogenase (GAPDH) was shown to have heme buffering 





Figure 5. Fluorescence ratio of HS1-M7A over time with (Green) and without (Blue) the 
addition of NOC-7 (NOC-7 releases NO molecules when added). Red lines indicate 
fluorescence ratio when HS1-M7A is 0% saturated while black lines are 100% saturated. 
Reprinted (adapted) with permission from Hanna et al. Copyright 2016 National 
Academy of Sciences.1 
 
 
 While the utility of HS1 and HS1-M7A cannot be denied when looking at the 
previous results, the limitations of the current generation of sensors can already begin to 
be seen.  The restricted binding affinity of these sensors limits accurate detection of heme 
in various compartments of the cell, such as the nucleus and the mitochondria.   This 
problem may be compounded when trying to insert sensors into new cell lines that span a 
wide range of labile heme concentrations.  With only two binding affinities available it is 
clear that creating a library of sensors with varying heme binding affinities will be 
required for future experimentation.  Also the inability to detect oxidized heme may limit 
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the capacity for these sensors to fully uncover heme dynamics in the cell. As such, the 
development of a sensor with oxidation state specificity may improve our understanding 
























SENSOR DESIGN AND SCREENING SENSORS 
 
2.1 Introduction 
 The prototype heme sensors, HS1 and HS1-M7A, are powerful tools for the 
monitoring and quantification of exchange labile heme.1 As described in section 1.4, 
these sensors have provided unprecedented access to heme pools relevant for trafficking 
and signaling. However, the affinities of these sensors are such that they are not adequate 
for heme sensing in subcellular compartments like the nucleus and mitochondria. HS1 
(Kd
II ~ 10 pM and Kd
III = 9 nM) is quantitatively saturated in all sub-cellular 
compartments, including the cytosol, nucleus, and mitochondria, making it unsuitable for 
heme monitoring. The low affinity sensor, HS1-M7A (Kd
II = 20 nM and Kd
III = 2 uM) is 
~20-50% saturated with heme in the cytosol, but has no heme bound to it in the nucleus 
and mitochondria, making it unsuitable for monitoring labile heme concentration and 
dynamics in these compartments. In order to expand the range of heme sensing, we 
generated a library of ~47 heme binding site mutations within the prototype HS1 sensor 
and screened for changes in heme saturation within the yeast cytosol. This approach 
resulted in 6 new HS1 variants that span a range of heme binding affinities between that 
of HS1 and HS1-M7A, generating new candidate sensors that may be ideal for heme 
imaging in subcellular compartments like the nucleus and mitochondria. 
The changes in free energy associated with heme binding to the heme binding 
domain, Cyt b562, arise from a combination of factors, including iron coordination by 
axial ligands, protein-porphyrin hydrophobic interactions, and electrostatic interactions 
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between the heme propionates and charged residues of the protein. Our initial strategy to 
expand the range of sensor heme binding affinities relied on altering the heme-iron axial 
ligands. Cyt b562 employs Met7 and His102, to coordinate heme.
26 Additionally, there is a 
potential low affinity heme-binding site formed by a surface histidine residue, His63, 
which may be capable of binding heme. Using Quick-Change mutagenesis, we not only 
demonstrated that the surface His63 does not contribute to sensor heme binding in cells, 
but also identified 6 sensor variants that have heme affinities that may be ideal for sub-
compartmental heme imaging through the systematic mutation of Met7 and His102 to 
alanine (Ala), cysteine (Cys), histidine (His), lysine (Lys), methionine (Met), serine (Ser), 
and tyrosine (Tyr). Taken together, our work has greatly expanded the available tool kit 
for heme imaging across cell types and subcellular compartments. 
 
2.2 Experimental Methods 
2.2.1 Yeast Strains, Genetic Manipulations, and Media 
  S. cerevisiae strains used in this study were derived from BY4741 (leu2∆0). Yeast 
transformations were performed by the lithium acetate procedure.27  Strains were 
maintained at 30°C on either enriched yeast extract-peptone based medium supplemented 
with 2% glucose (YPD), or synthetic complete medium (SC) supplemented with 2% 
glucose and leucine to maintain selection. Culturing of hem1∆ cells required 
supplementing SC media with 50 µg/mL of 5-aminolevulinic acid (5-ALA) or 15 mg/mL 





2.2.2 Plasmid Construction and Mutagenesis 
All plasmids where created from the cytosolic yeast HS1 sensor plasmid 
described previously by Hanna et al.1  This is the p415-GPD plasmid, a low copy 
centromeric plasmid with the HS1 sensor driven by the GPD promoter.28,1  His63, Met7 
and/or His102 residues were mutagenized by Quick Change mutagenesis (Agilent 
Technologies). The numbering refers to its position in Cytochrome b562.  His63 was 
mutated to Asparagine (Asn) while Met7 and His102 where mutated to Ala, Cys, His, Lys, 
Met, Ser and Tyr.  All plasmids and primers used are listed in the appendix as Table 2 
and Table 3. 
 
2.2.3 In-cell Fluorescence Spectroscopy 
Cells were cultured in SCE-LEU media for ~14-16 hours to mid-exponential 
phase (OD600 nm ~ 1-2.)  After culturing, cells were harvested, washed in water, and 
resuspended in phosphate buffered saline (PBS) solution at a concentration of 3 
OD600/mL. Cellular sensor fluorescence emission was recorded on a Synergy Mx multi-
modal plate reader using black Greiner Bio-one flat bottom fluorescence plates. EGFP 
and mKATE fluorescence were recorded using excitation and emission wavelength pairs 
of 488 nm and 510 nm and 588 nm and 620 nm, respectively, with 9 nm slit widths. For 
all measurements, cellular auto-fluorescence from both the EGFP and mKATE channels 






2.2.4 In Situ Sensor Calibration 
The fractional heme saturation of sensor variants was determined as described 
previously by Hanna et al.1 Briefly, the fraction of heme bound to sensor is governed by 
the following relationship: 
 





where Rexpt is fluorescence ratio of the sensor in cells under any condition, Rmin is the 
fluorescence ratio of the sensor when no heme is bound to it, and Rmax is the fluorescence 
ratio when the sensor is 100% saturated with heme. Rmin is derived from a parallel culture 
of hem1∆ cells, which lacks the 1st enzyme in the heme biosynthetic pathway, 5-ALA 
synthase, or from cells grown with 1 mM succinyl acetone, an inhibitor of the second 
enzyme in the heme biosynthetic pathway, 5-ALA dehydratase. Note, for all experiments 
described herein, Rmin was derived from hem1∆ cells. Rmax is derived from cells that are 
permeabilized with 200 ug/mL of digitonin and treated with 100 uM of hemin chloride 
and 1 mM ascorbate. An example of the determination of % bound for HS1 and HS1-
M7A, two prototype sensors, is described in Figure 6. By considering Rexpt, Rmin, and R 





Figure 6.  In situ calibration of heme sensors HS1 and HS1-M7A. EGFP/mKATE 
fluorescence ratios (R) of cells expressing HS1 or HS1-M7A. Rexp is derived from WT 
cells, Rmin is derived from hem1∆ cells, and Rmax is derived from WT cells that are 




2.3 Results/Discussion  
2.3.1 The effect of His63 on Sensor Heme Binding  
Cyt b562 has a surface His residue, His63, that may be a site for heme 
coordination.26  In order to determine the impact of His63 on sensor heme binding in cells, 
we mutated His63 to Asn, and determined the fraction of heme bound to the sensor using 
the calibration approaches described in section 2.2. As shown in in Figure 7, the 
fractional saturation of HS1 and HS1-M7A is unaffected by the H63N. This demonstrates 


























Figure 7. Fractional saturation of HS1, HS1-M7A, HS1 H63N and HS1-M7A H63N. 
 
 
2.3.2 An Expanded Library of HS1 Heme Binding Site Mutants 
In order to expand the range of heme binding affinities, we systematically 
mutated the Met7 and His102 heme-iron axial ligands to Ala, Cys, His, Lys, Met, Ser and 
Tyr, generating a library of ~47 new mutants. Upon introduction of these mutant sensors 
into yeast cells and fluorimetric determination of the fraction of heme bound to the 
sensors, we found that 20 variants had heme occupancies that resulted in 10-90 % heme 
bound (shown in green on Table 1) and 10 had heme occupancies below 10% or above 
90% (shown in red on Table 1). 7 sensors have yet to be fully characterized and this work 
is ongoing (labeled untested in Table 1). Ten sensors were unable to be transformed into 
yeast for unknown reasons (labeled as not available (NA) in Table 1.)   
For reference, the prototype sensors, HS1 and HS1-M7A, previously determined 
to be >90% or 20-50% bound with heme, are labeled yellow in Table 1. Sensor variants 






























heme imaging in yeast because these sensors likely have heme binding affinities that are 
too low or too high for optimal heme imaging. However, these variants may be 
appropriate for other cell types of extra-cytosolic compartments.  
 
 
Table 1. - Table of the fractional saturation of sensors from in situ calibration  
Green = 10-90% saturated 
Red = outside 10-90% saturated, 
Yellow = HS1 and HS1-M7A 
White = Untransformed (NA)/Untested 
 Residue 7 
Met Lys His Cys Tyr Ser Ala 
Residue 102 
Met <10 30.6 NA 38.4 <10 NA NA 
Lys 30.6 12.3 >90 <10 <10 NA 24.4 
His 93.0 63.8 29.3 >90 <10 NA 51.1 
Cys 60.9 53.3 81.6 Untested  19.6 NA 19.1 
Tyr 10.8 NA 37.2 Untested <10 NA Untested 
Ser 32.5 >90 Untested Untested <10 NA 62.1 






Figure 8.  Fractional saturation of all sensor mutants in a range of 10-90% saturation, 
after in situ calibration of sensors. 
 
 
 It can be seen in both Table 1 and Figure 8 that the primary coordination site 
mutagenesis approach created a large range of sensors capable of binding cytosolic LH in 
yeast.  This breadth of sensor affinities should allow for the detection of changes in LH in 
cellular compartments that were previously impossible to detect. Sensors with a fractional 
saturation that ranges between that of HS1 and HS1-M7A will be of use when looking at 
the LH pool in the nucleus and the mitochondria, something that HS1 and HS1-M7A 
were unable to do as they were completely saturated or unsaturated in these 
compartments, respectively.  It is also likely that this range of sensor affinities will be 






































Fractional Saturation of Various Sensor Mutants
22 
 
weak affinities, for example, will be of use in cell lines with a higher heme burden, e.g. 
blood and colon epithelial cells.29 
 While most individual mutations do not appear to have a clear effect on sensor 
binding, there are several mutations that do, including mutating residue 7 to Ser and 
residue 7 to Tyr.  It can be seen that the mutation of residue 7 to Ser possibly causes 
cytotoxicity, which is supported by the observation that all of these mutants where unable 
to be transformed.  Mutating residue 7 to Tyr appears to significantly limit heme binding 



















CONCLUSION AND FUTURE WORK 
 
3.1 Conclusion 
 Heme is a vital nutrient for cells despite its toxic nature; however, little is 
understood about how heme is regulated and trafficked in the cell.  In recent years this 
has begun to be corrected with the development of heme sensors such as the one 
developed by the Reddi Lab.  While these sensors are useful, they have significant 
limitations such as limited binding affinities, a limited color pallet, and limited preference 
for heme oxidation states.  In an effort to broaden the binding affinities of these sensors 
and possibly create a sensor with preferential binding to oxidized heme, a series of 
mutations were made to the axial binding motif of HS1.  Many of the mutations made 
appear to have binding affinities that range from virtually no binding to affinities on the 
order of HS1 itself.  These results show that the development of a heme sensor library 
was a success in terms of creating a multitude of sensors with an expanded range of 
fractional heme occupancies. However, future work need to be done to determine sensor 
heme binding affinities and if these sensors can sense heme in compartments that HS1 
and HS1-M7A were unable to sense heme in.  Further, as heme can exist in primary 
oxidation states, ferric and ferrous, sensors with oxidation state specificity may uncover 
new aspects of the cell biology of labile heme pools.  Altogether, the expanded library of 
heme sensors can be utilized to answer questions on how heme is regulated throughout 




3.2 Future Work 
 Further in vitro characterization is required to guarantee that these sensors are 
working correctly and detecting heme as intended here.  Answering questions of the 
actual heme binding affinities and preferences in heme oxidation state are important 
before these sensors can be used to answer questions in vivo.  Once these sensors are 
confirmed to be working as they were intended it will be important to improve their 
design further.  Altering the color pallet of theses sensor, for example, will be difficult 
but useful when considering looking at heme transportation throughout the cell.  On the 
same vein, targeting these sensors to the organelles, such as the mitochondria and the 
nucleus, will likely be a fruitful endeavor as the concentration of labile heme in these 
compartments has been a difficult question to answer as of yet.  Further development of 
these sensors to be used in various cell types, including bacterial and mammalian, will 
likely be a powerful step in understanding the questions of how heme effects human 
disease.  Much is to be done to completely develop the tools necessary to answer all the 
questions of heme’s role in biology, but the production of this library of sensors will be 











PLASMIDS AND PRIMERS 
Table 2. Description of plasmids used 
Plasmid Name Plasmid Description 
pJA004-1 Expresses mKATEeGFPb562 (HS1 His102/Met7 H63N) Sensor 
pJA005-1 Expresses mKATEeGFPb562 (HS1 His102/Ala7 H63N) Sensor 
pJA006-1 Expresses mKATEeGFPb562 (HS1 Lys102/Ala7 H63N) Sensor 
pJA007-1 Expresses mKATEeGFPb562 (HS1 Cys102/Ala7 H63N) Sensor 
pJA008-1 Expresses mKATEeGFPb562 (HS1 Ser102/Ala7 H63N) Sensor 
pJA009-1 Expresses mKATEeGFPb562 (HS1 Tyr102/Ala7 H63N) Sensor 
pJA010-1 Expresses mKATEeGFPb562 (HS1 Ala102/Ala7 H63N) Sensor 
pJA011-1 Expresses mKATEeGFPb562 (HS1 Met102/Ala7 H63N) Sensor 
pJA012A-1 Expresses mKATEeGFPb562 (HS1 Lys102/Met7 H63N) Sensor 
pJA013-1 Expresses mKATEeGFPb562 (HS1 Ser102/Met7 H63N) Sensor 
pJA014-1 Expresses mKATEeGFPb562 (HS1 Cys102/Met7 H63N) Sensor 
pJA015-1 Expresses mKATEeGFPb562 (HS1 Tyr102/Met7 H63N) Sensor 
pJA016-1 Expresses mKATEeGFPb562 (HS1 Ala102/Met7 H63N) Sensor 
pJA017A-3 Expresses mKATEeGFPb562 (HS1 Met102/Met7 H63N) Sensor 
pJA018 Expresses mKATEeGFPb562 (HS1 His102/Lys7 H63N) Sensor 
pJA019-1 Expresses mKATEeGFPb562 (HS1 His102/Tyr7 H63N) Sensor 
pJA020 Expresses mKATEeGFPb562 (HS1 Met102/Lys7 H63N) Sensor 
pJA021A-1 Expresses mKATEeGFPb562 (HS1 Ala102/His7 H63N) Sensor 
pJA022-1 Expresses mKATEeGFPb562 (HS1 Met102/Ser7 H63N) Sensor 
pJA023-1 Expresses mKATEeGFPb562 (HS1 Tyr102/His7 H63N) Sensor 
pJA024-1 Expresses mKATEeGFPb562 (HS1 Lys102/Tyr7 H63N) Sensor 
pJA025-1 Expresses mKATEeGFPb562 (HS1 Cys102/Tyr7 H63N) Sensor 
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pJA026A-1 Expresses mKATEeGFPb562 (HS1 Ser102/Tyr7 H63N) Sensor 
pJA027A-1 Expresses mKATEeGFPb562 (HS1 Tyr102/Tyr7 H63N) Sensor 
pJA028A-1 Expresses mKATEeGFPb562 (HS1 Ala102/Tyr7 H63N) Sensor 
pJA029-1 Expresses mKATEeGFPb562 (HS1 Met102/Tyr7 H63N) Sensor 
pJA030A-1 Expresses mKATEeGFPb562 (HS1 Met102/His7 H63N) Sensor 
pJA031-1 Expresses mKATEeGFPb562 (HS1 Lys102/Lys7 H63N) Sensor 
pJA032-1 Expresses mKATEeGFPb562 (HS1 Cys102/Lys7 H63N) Sensor 
pJA033-1 Expresses mKATEeGFPb562 (HS1 Ser102/Lys7 H63N) Sensor 
pJA034-1 Expresses mKATEeGFPb562 (HS1 Ala102/Lys7 H63N) Sensor 
pJA035-1 Expresses mKATEeGFPb562 (HS1 Lys102/His7 H63N) Sensor 
pJA036A-1 Expresses mKATEeGFPb562 (HS1 His102/His7 H63N) Sensor 
pJA037A-1 Expresses mKATEeGFPb562 (HS1 Cys102/His7 H63N) Sensor 
pJA038-1 Expresses mKATEeGFPb562 (HS1 Ser102/His7 H63N) Sensor 
pJA039-1 Expresses mKATEeGFPb562 (HS1 His102/Cys7 H63N) Sensor 
pJA040-1 Expresses mKATEeGFPb562 (HS1 Lys102/Cys7 H63N) Sensor 
pJA041A-1 Expresses mKATEeGFPb562 (HS1 Met102/Cys7 H63N) Sensor 
pJA042-1 Expresses mKATEeGFPb562 (HS1 Cys102/Cys7 H63N) Sensor 
pJA043-1 Expresses mKATEeGFPb562 (HS1 Tyr102/Cys7 H63N) Sensor 
pJA044A-1 Expresses mKATEeGFPb562 (HS1 Ser102/Cys7 H63N) Sensor 
pJA045-1 Expresses mKATEeGFPb562 (HS1 Ala102/Cys7 H63N) Sensor 
pJA046-1 Expresses mKATEeGFPb562 (HS1 Lys102/Ser7 H63N) Sensor 
pJA047-1 Expresses mKATEeGFPb562 (HS1 His102/Ser7 H63N) Sensor 
pJA048-1 Expresses mKATEeGFPb562 (HS1 Cys102/Ser7 H63N) Sensor 
pJA049-1 Expresses mKATEeGFPb562 (HS1 Tyr102/Ser7 H63N) Sensor 
pJA050-1 Expresses mKATEeGFPb562 (HS1 Ser102/Ser7 H63N) Sensor 




Table 3. Primers used for QuikChange reactions 
Primer Sequence  Purpose 
prRC008 GCAGATCTGGAAGACAACGCGGAAACTCTGAACG mutates residue 7  --
> Ala in cytb562 
prRC008-r CGTTCAGAGTTTCCGCGTTGTCTTCCAGATCTGC mutates residue 7  --
> Ala in cytb562 
prRC009 CCACTCGTAATGCATATGCTCAGAAATACAGAGG mutates residue 102 -
-> Alain cytb562 
prRC009-r CCTCTGTATTTCTGAGCATATGCATTACGAGTGG mutates residue 102 -
-> Ala in cytb562 
prRC010 CCACTCGTAATGCATATATGCAGAAATACAGAGG mutates residue 102 -
-> Met in cytb562 
prRC010-r CCTCTGTATTTCTGCATATATGCATTACGAGTGG mutates residue 102 -
-> Met in cytb562 
pRH015 ACTCGTAATGCATATAAACAGAAATACAGAGGT mutates residue 102 -
-> Lys in cytb562 
pRH015-r TGGAGACATAAAGACAAATATACGTAATGCTCA mutates residue 102 -
-> Lys in cytb562 
pRH016 GATCTGGAAGACAACAAGGAAACTCTGAACGAT mutates residue 7 --> 
Lys in cytb562 
pRH016-r TAGCAAGTCTCAAAGGAACAACAGAAGGTCTAG mutates residue 7 --> 
Lys in cytb562 
pRH017 ACTCGTAATGCATATTGTCAGAAATACAGAGGT mutates residue 102 -
-> Cys in cytb562 
pRH017-r TGGAGACATAAAGACTGTTATACGTAATGCTCA mutates residue 102--
> Cys in cytb562 
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pRH018 ACTCGTAATGCATATTCTCAGAAATACAGAGGT mutates residue 102 -
-> Ser in cytb562 
pRH018-r TGGAGACATAAAGACTCTTATACGTAATGCTCA mutates residue 102--
> Ser in cytb562 
pRH019 ACTCGTAATGCATATTATCAGAAATACAGAGGT mutates residue 102 -
-> Tyr in cytb562 
pRH019-r TGGAGACATAAAGACTATTATACGTAATGCTCA mutates residue 102--
> Tyr in cytb562 
pRH020 GATCTGGAAGACAACTACGAAACTCTGAACGAT mutates residue 7 --> 
Tyr in cytb562 
pRH020-r TAGCAAGTCTCAAAGCATCAACAGAAGGTCTAG mutates residue 7 --> 
Tyr in cytb562 
prJA004 GCAGATCTGGAAGACAACCACGAAACTCTGAACG mutates residue 7 --> 
his in cytb562 
prJA004-r CGTTCAGAGTTTCGTGGTTGTCTTCCAGATCTGC mutates residue 7 --> 
his in cytb562 
prJA005 GCAGATCTGGAAGACAACTCGGAAACTCTGAACG mutates residue 7 --> 
Ser in cytb562 
prJA005-r CGTTCAGAGTTTCCGAGTTGTCTTCCAGATCTGC mutates residue 7 --> 
Ser in cytb562 
prJA006 GCAGATCTGGAAGACAACTGTGAAACTCTGAACG Mutates residue7 --> 
cys in cytb562 
prJA006-r CGTTCAGAGTTTCACAGTTGTCTTCCAGATCTGC Mutates residue7 --> 
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